The public view is the crawlable proof. The same sourced dataset is available through REST and MCP for agents, research scripts, and back-office tools.
| Date | Insider | Role | Action | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Jul 2, 2026 | Vivo Opportunity, LLC | 10% Owner | Buy(P) | 1K | $1.55 | $2K |
| Jul 2, 2026 | Vivo Opportunity, LLC | 10% Owner | Buy(P) | 147 | $1.55 | $228 |
| Jul 1, 2026 | Vivo Opportunity, LLC | 10% Owner | Buy(P) | 4K | $1.55 | $6K |
| Jul 1, 2026 | Vivo Opportunity, LLC | 10% Owner | Buy(P) | 398 | $1.55 | $617 |
| Jun 30, 2026 | Vivo Opportunity, LLC | 10% Owner | Buy(P) | 545 | $1.54 | $839 |
| Jun 30, 2026 | Vivo Opportunity, LLC | 10% Owner | Buy(P) | 55 | $1.54 | $85 |
| Jun 8, 2026 | Vivo Opportunity, LLC | 10% Owner | Buy(P) | 30K | $1.52 | $45K |
| Jun 8, 2026 | Vivo Opportunity, LLC | 10% Owner | Buy(P) | 3K | $1.52 | $5K |
| Jun 5, 2026 | Vivo Opportunity, LLC | 10% Owner | Buy(P) | 50K | $1.57 | $78K |
| Jun 5, 2026 | Vivo Opportunity, LLC | 10% Owner | Buy(P) | 5K | $1.57 | $8K |
| Jun 4, 2026 | Vivo Opportunity, LLC | 10% Owner | Buy(P) | 6K | $1.57 | $10K |
| Jun 4, 2026 | Vivo Opportunity, LLC | 10% Owner | Buy(P) | 618 | $1.57 | $970 |
| Jun 3, 2026 | Vivo Opportunity, LLC | 10% Owner | Buy(P) | 7K | $1.55 | $11K |
| Jun 3, 2026 | Vivo Opportunity, LLC | 10% Owner | Buy(P) | 714 | $1.55 | $1K |
| Jun 2, 2026 | Vivo Opportunity, LLC | 10% Owner | Buy(P) | 21K | $1.52 | $32K |
| Jun 2, 2026 | Vivo Opportunity, LLC | 10% Owner | Buy(P) | 2K | $1.52 | $3K |
| Jun 1, 2026 | Vivo Opportunity, LLC | 10% Owner | Buy(P) | 15K | $1.55 | $23K |
| Jun 1, 2026 | Vivo Opportunity, LLC | 10% Owner | Buy(P) | 1K | $1.55 | $2K |
| May 29, 2026 | Vivo Opportunity, LLC | 10% Owner | Buy(P) | 16K | $1.57 | $25K |
| May 29, 2026 | Vivo Opportunity, LLC | 10% Owner | Buy(P) | 2K | $1.57 | $3K |
| May 21, 2026 | Vivo Opportunity, LLC | 10% Owner | Buy(P) | 31K | $1.69 | $52K |
| May 21, 2026 | Vivo Opportunity, LLC | 10% Owner | Buy(P) | 3K | $1.69 | $5K |
| May 20, 2026 | Vivo Opportunity, LLC | 10% Owner | Buy(P) | 51K | $1.56 | $80K |
| May 20, 2026 | Vivo Opportunity, LLC | 10% Owner | Buy(P) | 5K | $1.56 | $8K |
| May 19, 2026 | ADAR1 Capital Management, LLC | 10% Owner | Buy(P) | 200K | $1.50 | $300K |
| May 19, 2026 | ADAR1 Capital Management, LLC | 10% Owner | Buy(P) | 200K | $1.56 | $312K |
| May 19, 2026 | ADAR1 Capital Management, LLC | 10% Owner | Buy(P) | 69K | $1.60 | $110K |
| Dec 19, 2025 | Hull Andrew | Director | Grant(A) | 2K | — | $0 |
| Dec 19, 2025 | Adams Eric A | President & CEO, Director | Grant(A) | 35K | — | $0 |
| Dec 19, 2025 | Hsu Eric C | Sr. VP, Pre-Clinical Res/Dev | Grant(A) | 13K | — | $0 |
| Dec 19, 2025 | Bathery John Steven | Director | Grant(A) | 2K | — | $0 |
| Dec 19, 2025 | Woudenberg Michael | Chief Operating Officer | Grant(A) | 18K | — | $0 |
| Dec 19, 2025 | Jagpal Netta | Chief Financial Officer | Grant(A) | 18K | — | $0 |
| Dec 19, 2025 | Klompas Neil A | Director | Grant(A) | 2K | — | $0 |
| Dec 19, 2025 | Lemerond Nicole | Director | Grant(A) | 2K | — | $0 |
| Dec 19, 2025 | Johnson Shane Aaron | Sr VP & General Manager | Grant(A) | 9K | — | $0 |
| Dec 15, 2025 | Hsu Eric C | Sr. VP, Pre-Clinical Res/Dev | Expiration(H) | 70 | — | $0 |
| Dec 15, 2025 | Woudenberg Michael | Chief Operating Officer | Expiration(H) | 60 | — | $0 |
| Dec 15, 2025 | Adams Eric A | President & CEO, Director | Expiration(H) | 250 | — | $0 |
| Dec 15, 2025 | Hull Andrew | Director | Expiration(H) | 14 | — | $0 |
| Oct 17, 2025 | Klompas Neil A | Director | Grant(A) | 4K | — | $0 |
| Jan 11, 2025 | Hull Andrew | Director | Expiration(H) | 2 | — | $0 |
| Dec 20, 2024 | Hull Andrew | Director | Grant(A) | 550 | — | $0 |
| Dec 20, 2024 | Baldasare Bryan T | Director | Grant(A) | 550 | — | $0 |
| Dec 20, 2024 | Adams Eric A | President & CEO, Director | Grant(A) | 6K | — | $0 |
| Dec 20, 2024 | Hsu Eric C | Sr. VP, Pre-Clinical Res/Dev | Grant(A) | 3K | — | $0 |
| Dec 20, 2024 | Grove Janet P | Director | Grant(A) | 550 | — | $0 |
| Dec 20, 2024 | Woudenberg Michael | Chief Operating Officer | Grant(A) | 4K | — | $0 |
| Dec 20, 2024 | Lemerond Nicole | Director | Grant(A) | 550 | — | $0 |
| Dec 20, 2024 | Jagpal Netta | Chief Financial Officer | Grant(A) | 4K | — | $0 |
| Dec 20, 2024 | Johnson Shane Aaron | Sr VP & General Manager | Grant(A) | 2K | — | $0 |
| Jul 31, 2024 | Mancini Alexandra Diane Janet | Insider | Sell(S) | 240 | $0.18 | $43 |
| May 27, 2024 | Mancini Alexandra Diane Janet | Sr VP, Clinical Reg Affairs | Expiration(H) | 485 | — | $0 |
| May 27, 2024 | Adams Eric A | President & CEO, Director | Expiration(H) | 1K | — | $0 |
| May 27, 2024 | Hsu Eric C | Sr. VP, Pre-Clinical Res/Dev | Expiration(H) | 545 | — | $0 |
| May 27, 2024 | Woudenberg Michael | Chief Operating Officer | Expiration(H) | 394 | — | $0 |
| Mar 4, 2024 | Hsu Eric C | Sr. VP, Pre-Clinical Res/Dev | Expiration(H) | 309 | — | $0 |
| Feb 21, 2024 | Hull Andrew | Director | Buy(P) | 38K | $0.39 | $15K |
| Feb 20, 2024 | Adams Eric A | President & CEO, Director | Buy(P) | 42K | $0.36 | $15K |
| Jan 21, 2024 | Mancini Alexandra Diane Janet | Sr VP, Clinical Reg Affairs | Expiration(H) | 121 | — | $0 |
| Jan 14, 2024 | Hull Andrew | Director | Expiration(H) | 42 | — | $0 |
| Dec 23, 2023 | Hull Andrew | Director | Grant(A) | 7K | — | $0 |
| Dec 23, 2023 | Mancini Alexandra Diane Janet | Sr VP, Clinical Reg Affairs | Grant(A) | 45K | — | $0 |
| Dec 23, 2023 | Baldasare Bryan T | Director | Grant(A) | 7K | — | $0 |
| Dec 23, 2023 | Adams Eric A | President & CEO, Director | Grant(A) | 136K | — | $0 |
| Dec 23, 2023 | Hsu Eric C | Sr. VP, Pre-Clinical Res/Dev | Grant(A) | 45K | — | $0 |
| Dec 23, 2023 | Grove Janet P | Director | Grant(A) | 7K | — | $0 |
| Dec 23, 2023 | Tegge Jonathan | Interim CFO | Grant(A) | 30K | — | $0 |
| Dec 23, 2023 | Woudenberg Michael | Chief Operating Officer | Grant(A) | 65K | — | $0 |
| Dec 23, 2023 | Lemerond Nicole | Director | Grant(A) | 7K | — | $0 |
| Dec 23, 2023 | Johnson Shane Aaron | Sr VP & General Manager | Grant(A) | 40K | — | $0 |
| Dec 5, 2023 | Woudenberg Michael | Chief Operating Officer | Expiration(H) | 848 | — | $0 |
| Aug 31, 2023 | Hsu Eric C | Sr. VP, Pre-Clinical Res/Dev | Expiration(H) | 327 | — | $0 |
| May 16, 2023 | Adams Eric A | President & CEO, Director | Expiration(H) | 2K | — | $0 |
| May 16, 2023 | Mancini Alexandra Diane Janet | Sr VP, Clinical Reg Affairs | Expiration(H) | 485 | — | $0 |
| May 16, 2023 | Hsu Eric C | Sr. VP, Pre-Clinical Res/Dev | Expiration(H) | 152 | — | $0 |
| Mar 8, 2023 | Adams Eric A | President & CEO, Director | Expiration(H) | 545 | — | $0 |
| Mar 8, 2023 | Hsu Eric C | Sr. VP, Pre-Clinical Res/Dev | Expiration(H) | 545 | — | $0 |
| Mar 8, 2023 | Mancini Alexandra Diane Janet | Sr VP, Clinical Reg Affairs | Expiration(H) | 61 | — | $0 |
| Dec 16, 2022 | Hull Andrew | Director | Grant(A) | 840 | — | $0 |
| Dec 16, 2022 | Mancini Alexandra Diane Janet | Sr VP, Clinical Reg Affairs | Grant(A) | 4K | — | $0 |
| Dec 16, 2022 | Baldasare Bryan T | Director | Grant(A) | 840 | — | $0 |
| Dec 16, 2022 | Adams Eric A | President & CEO, Director | Grant(A) | 15K | — | $0 |
| Dec 16, 2022 | Hsu Eric C | Sr. VP, Pre-Clinical Res/Dev | Grant(A) | 4K | — | $0 |
| Dec 16, 2022 | Grove Janet P | Director | Grant(A) | 840 | — | $0 |
| Dec 16, 2022 | Tegge Jonathan | Interim CFO | Grant(A) | 1K | — | $0 |
| Dec 16, 2022 | Woudenberg Michael | Chief Operating Officer | Grant(A) | 8K | — | $0 |
| Dec 16, 2022 | Lemerond Nicole | Director | Grant(A) | 840 | — | $0 |
| Dec 16, 2022 | Johnson Shane Aaron | Sr VP & General Manager | Grant(A) | 4K | — | $0 |
| Dec 16, 2022 | Li Sarah | VP Accounting & Controller | Grant(A) | 4K | — | $0 |
| Nov 14, 2022 | Woudenberg Michael | Chief Operating Officer | Disposed to issuer(D) | 8K | — | $0 |
| Nov 14, 2022 | Adams Eric A | President & CEO, Director | Disposed to issuer(D) | 15K | — | $0 |
| Nov 14, 2022 | Hsu Eric C | Sr. VP, Pre-Clinical Res/Dev | Disposed to issuer(D) | 4K | — | $0 |
| Nov 14, 2022 | Mancini Alexandra Diane Janet | Sr VP, Clinical Reg Affairs | Disposed to issuer(D) | 4K | — | $0 |
| Nov 14, 2022 | Johnson Shane Aaron | Sr VP & General Manager | Disposed to issuer(D) | 4K | — | $0 |
| Aug 10, 2022 | Lemerond Nicole | Director | Grant(A) | 14K | — | $0 |
| Jun 2, 2022 | Adams Eric A | President & CEO, Director | Expiration(H) | 14K | — | $0 |
| Jun 2, 2022 | Mancini Alexandra Diane Janet | Sr VP, Clinical Reg Affairs | Expiration(H) | 2K | — | $0 |
| May 17, 2022 | Baldasare Bryan T | Director | Grant(A) | 14K | — | $0 |
| Apr 14, 2022 | Adams Eric A | President & CEO, Director | Buy(P) | 14K | $0.89 | $13K |
Insider transactions sourced from SEC EDGAR Form 4 filings, normalized within minutes of acceptance. "Buy"/"Sell" mark open-market transactions (codes P/S), the tradeable signal. Awards, option exercises and tax-withholding are shown with their raw code. All data is public domain.
Coverage: Form 4 filings indexed 2021-03-29 → 2026-07-11. Earlier history is backfilling; this window widens as it deepens.
Programmatic access via the Arkolith API & MCP server (insider.transactions, insider.company).